These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 16336763)

  • 41. Preliminary safety and efficacy data of brecanavir, a novel HIV-1 protease inhibitor: 24 week data from study HPR10006.
    Lalezari JP; Ward DJ; Tomkins SA; Garges HP
    J Antimicrob Chemother; 2007 Jul; 60(1):170-4. PubMed ID: 17491001
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New formulation of saquinavir (Fortovase) is more effective.
    Tam CW
    Fac Notes (New Orleans La); 1998; 10(2):11. PubMed ID: 11365126
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART.
    Collazos J; Asensi V; Cartón JA
    AIDS; 2007 Apr; 21(7):835-43. PubMed ID: 17415038
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
    Maillard A; Chapplain JM; Tribut O; Bentué-Ferrer D; Tattevin P; Arvieux C; Michelet C; Ruffault A
    J Clin Virol; 2007 Feb; 38(2):131-8. PubMed ID: 17208042
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Influence of a monocyte chemoattractant protein 1 mutated allele on the response to protease inhibitor-based antiretroviral therapy.
    Coll B; Alonso-Villaverde C; Parra S; Rabassa A; Martorell L; Joven J; Masana L
    HIV Med; 2006 Sep; 7(6):356-60. PubMed ID: 16903979
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK Trial randomized to ritonavir-boosted lopinavir alone.
    Flandre P; Delaugerre C; Ghosn J; Chaix ML; Horban A; Girard PM; Gladysz A; Cohen-Codar I; Van PN; Taburet AM; Rouzioux C; Delfraissy JF;
    Antivir Ther; 2009; 14(1):93-7. PubMed ID: 19320241
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
    Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
    Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dose reduction effective in alleviating symptoms of saquinavir toxicity.
    Stephan C; Carlebach A; Rottmann C; Haberl A; Dauer B; von Hentig N; Kurowski M; Staszewski S
    Int J STD AIDS; 2007 Feb; 18(2):81-4. PubMed ID: 17331276
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy.
    Rodés B; Sheldon J; Toro C; Jiménez V; Alvarez MA; Soriano V
    J Antimicrob Chemother; 2006 Apr; 57(4):709-13. PubMed ID: 16464891
    [TBL] [Abstract][Full Text] [Related]  

  • 50. No tease this time--pros and cons of a long-awaited anti-HIV drug.
    Chang HE
    Posit Aware; 1996; 7(1):18-20. PubMed ID: 11363118
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.
    Mocroft A; Phillips AN; Ledergerber B; Katlama C; Chiesi A; Goebel FD; Knysz B; Antunes F; Reiss P; Lundgren JD
    AIDS; 2006 May; 20(8):1141-50. PubMed ID: 16691065
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The use of saquinavir/ritonavir 1000/100 mg twice daily in patients with tuberculosis receiving rifampin.
    Losso MH; Lourtau LD; Toibaro JJ; Saenz C; González C
    Antivir Ther; 2004 Dec; 9(6):1031-3. PubMed ID: 15651762
    [No Abstract]   [Full Text] [Related]  

  • 53. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
    Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
    AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
    Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
    AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
    Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
    J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. Study of Protease Inhibitor Combinations in Europe.
    Moyle G; Pozniak A; Opravil M; Clumeck N; DelFraissy JF; Johnson M; Pelgrom J; Reynes J; Vittecoq D; DeLora P; Salgo M; Duff F
    J Acquir Immune Defic Syndr; 2000 Feb; 23(2):128-37. PubMed ID: 10737427
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nelfinavir combination therapy: ten-month report.
    AIDS Treat News; 1997 Apr; (No 269):3. PubMed ID: 11364253
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dual PI therapy emerges as most viable combination.
    AIDS Alert; 1997 Dec; 12(12):133-5. PubMed ID: 11364830
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nelfinavir (Viracept) moves up the ranks.
    Grodeck B
    Posit Aware; 1997; 8(2):16-7. PubMed ID: 11364452
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Influence of single-nucleotide polymorphisms in the multidrug resistance-1 gene on the cellular export of nelfinavir and its clinical implication for highly active antiretroviral therapy.
    Zhu D; Taguchi-Nakamura H; Goto M; Odawara T; Nakamura T; Yamada H; Kotaki H; Sugiura W; Iwamoto A; Kitamura Y
    Antivir Ther; 2004 Dec; 9(6):929-35. PubMed ID: 15651752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.